Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29544040 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MTNR1AMTNR1BAOC3PTGS1 | |
| SCHEMBL21326187 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MTNR1AMTNR1BAOC3PTGS1 | |
| SCHEMBL18890289 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MTNR1AMTNR1BAOC3PTGS1 | |
| SCHEMBL29544093 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MTNR1AMTNR1BAOC3PTGS1 | |
| Hydrochloric Acid SCHEMBL7051120 | 0.98 | L3MBTL1 (0.55) | L3MBTL1MTNR1AMTNR1BAOC3PTGS1 | |
| SCHEMBL5045126 | 0.87 | PTGS1 (0.67) | MTNR1AMTNR1BPTGS1 | |
| SCHEMBL17295986 | 0.85 | PTGS1 (0.45) | L3MBTL1MTNR1AMTNR1BPTGS1 | |
| SCHEMBL27619948 | 0.85 | L3MBTL1 (0.55) | L3MBTL1MTNR1AMTNR1BAOC3CES2 | |
| SCHEMBL29543522 | 0.85 | L3MBTL1 (0.63) | L3MBTL1MTNR1AMTNR1BAOC3CES2 | |
| SCHEMBL2383723 | 0.84 | NPC1 (0.56) | L3MBTL1MTNR1AMTNR1BCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112174800-B | Preparation method of 2, 5-dimethoxy phenylacetic acid | 爱斯特（成都）生物制药股份有限公司 | 2023-07-28 | — | — | CN | claimed |
| CN-112321412-A | Preparation method of 2, 5-dimethoxy phenylacetic acid | 爱斯特（成都）生物制药股份有限公司 | 2021-02-05 | — | — | CN | claimed |
| CN-112321413-A | Preparation method of 2, 5-dimethoxy phenylacetic acid | 爱斯特（成都）生物制药股份有限公司 | 2021-02-05 | — | — | CN | claimed |
| CN-112239402-A | Preparation method of 2, 5-dimethoxy phenylacetic acid | 爱斯特（成都）生物制药股份有限公司 | 2021-01-19 | — | — | CN | claimed |
| CN-112174800-A | Preparation method of 2, 5-dimethoxy phenylacetic acid | 爱斯特（成都）生物制药股份有限公司 | 2021-01-05 | — | — | CN | claimed |
| CN-112174800-B | Preparation method of 2, 5-dimethoxy phenylacetic acid | 爱斯特（成都）生物制药股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-112174800-B | Preparation method of 2, 5-dimethoxy phenylacetic acid | 爱斯特（成都）生物制药股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-112174800-B | Preparation method of 2, 5-dimethoxy phenylacetic acid | 爱斯特（成都）生物制药股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-3868758-B1 | THIADIAZOLE DERIVATIVES AND USE THEREOF AS A GLS1 INHIBITORS FOR THE TREATMENT OF CANCER | MEDSHINE DISCOVERY INC (CN) | 2023-01-04 | — | — | EP | disclosed |
| CN-108349967-B | 1,3, 4-thiadiazole compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2022-02-15 | — | — | CN | disclosed |
| US-11230544-B1 | Substituted 1,3,4-thiadiazoles as GLS1 inhibitors | MEDSHINE DISCOVERY INC. (CN) | 2022-01-25 | — | — | US | disclosed |
| CN-112321413-A | Preparation method of 2, 5-dimethoxy phenylacetic acid | 爱斯特（成都）生物制药股份有限公司 | 2021-02-05 | — | — | CN | disclosed |
| WO-2017089587-A1 | BIS-PYRIDAZINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089587-A1 | BIS-PYRIDAZINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | WO | disclosed |
| EP-3148994-A1 | 1, 3, 4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015181539-A1 | 1, 3, 4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2015-12-03 | — | — | WO | disclosed |
| WO-2015181539-A1 | 1, 3, 4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2015-12-03 | — | — | WO | disclosed |
| US-7888374-B2 | Inhibitors of c-jun N-terminal kinases | ABBOTT LABORATORIES (US) | 2011-02-15 | — | — | US | disclosed |
| WO-2006083673-A2 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF C-JUN N-TERMINAL KINASES | ABBOTT LABORATORIES (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | ABBVIE INC. | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | MAPKAPK3, MAP3K3, MAPK3 | L3MBTL1 1511/4885MTNR1A 3253/4885MTNR1B 3010/4885 |
| US-11230544-B1 | Substituted 1,3,4-thiadiazoles as GLS1 inhibitors | GLS2, GLS, GYS2 | L3MBTL1 2574/4885MTNR1A 1712/4885MTNR1B 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.